CD4(+) T(H)1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8(+) T Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jae Yeo | - |
dc.contributor.author | Jin, Dong-Hoon | - |
dc.contributor.author | Lee, Chang-Min | - |
dc.contributor.author | Jang, Min Ja | - |
dc.contributor.author | Lee, Sun Young | - |
dc.contributor.author | Shin, Hyo Seon | - |
dc.contributor.author | Chung, Yoon Hee | - |
dc.contributor.author | Kim, Kyung Yong | - |
dc.contributor.author | Kim, Sung Su | - |
dc.contributor.author | Lee, Won Bok | - |
dc.contributor.author | Shin, Yong Kyoo | - |
dc.contributor.author | Lee, Wang Jae | - |
dc.contributor.author | Park, Yeong-Min | - |
dc.contributor.author | Kim, Daejin | - |
dc.date.available | 2019-05-30T01:34:52Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 1524-9557 | - |
dc.identifier.issn | 1537-4513 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/22419 | - |
dc.description.abstract | The requirement for CD4(+) T cells in priming and maintaining cytotoxic T-lymphocyte responses presents a long-standing paradox in cellular immunology. In this study, we used sequential coadministration of a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii-peptide region is replaced with CD4(+) T-helper epitope, PADRE [Pan human leukocyte antigen-DR reactive epitope (Ii-PADRE)] or BclxL with a DNA vaccine encoding Sig/E7/LAMP-1 to verify the role of CD4(+) T cells for the generation of effectors and memory E7-specific CD8(+) T-cell immune responses. Sequential vaccination, with Ii-PADRE + Sig/E7/LAMP-1 priming followed by BclxL + Sig/E7/LAMP-1 boosting led to generation of E7-specific CD8(+) T cells, and was nearly equivalent in effect to coadministration with Ii-PADRE+Sig/E7/LAMP-1 or Bcl-xL + Sig/E7/LAMP-1 at both prime and boost. The mice vaccinated with the Ii-PADRE+Sig/E7/LAMP-1 prime-Bcl-xL + Sig/E7/LAMP-1 boost regimen exhibited better long-term E7-specific immune responses and tumor prevention effects in vivo than the mice vaccinated with the reverse sequential coadministration. After CD4+ T-cell depletion, mice primed with Ii-PADRE+Sig/E7/LAMP-1 generated low numbers of E7-specific CD8(+) T cells and suppressed long-term memory CD8(+) T-cell response regardless of the sequence or combination of DNA vaccines administered. Mice primed with Bcl-xL + Sig/E7/LAMP-1 only suppressed long-term memory CD8(+) T-cell response after depletion of CD4(+) T cells before priming. Our findings suggest that activated CD4(+) T cells at prime phase are important to generate the antigen-specific CD8(+) T-cell immune responses and CD4(+) T cells, which are naive or activated, play a role to maintain the long-term memory responses. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | CD4(+) T(H)1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8(+) T Cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/CJI.0b013e3181d75cef | - |
dc.identifier.bibliographicCitation | JOURNAL OF IMMUNOTHERAPY, v.33, no.5, pp 510 - 522 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000278104600009 | - |
dc.identifier.scopusid | 2-s2.0-77953042787 | - |
dc.citation.endPage | 522 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 510 | - |
dc.citation.title | JOURNAL OF IMMUNOTHERAPY | - |
dc.citation.volume | 33 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | DNA vaccine | - |
dc.subject.keywordAuthor | E7 | - |
dc.subject.keywordAuthor | Ii-PADRE | - |
dc.subject.keywordAuthor | Bcl-xL | - |
dc.subject.keywordAuthor | prime-boost | - |
dc.subject.keywordPlus | INTRACELLULAR TARGETING STRATEGIES | - |
dc.subject.keywordPlus | ANTIGEN-PRESENTING CELLS | - |
dc.subject.keywordPlus | VACCINE POTENCY | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | CTL | - |
dc.subject.keywordPlus | LYMPHOCYTES | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | CD40 | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.